Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma

Donato, Michèle; Park, Steven; Baker, Melissa; Korngold, Robert; Morawski, Alison; Geng, Xue; Tan, Ming; Ip, Andrew; Goldberg, Stuart L.; Rowley, Scott D.; Chow, Kar Fai; Brown, Emily; Zenreich, Joshua; McKiernan, Phyllis; Buttner, Kathryn; Ullrich, Anna; Long, Laura J.; Feinman, Rena; Ricourt, Andrea; Kemp, Marlo; Vendivil, Mariefel; Suh, Hyung Chan; Balani, Bindu; Cicogna, Cristina; Sebti, Rani; Al-Khan, Abdulla; Sperber, Steven J.; Desai, Samit; Fanning, Stacey L.; Arad, Danit; Go, Ronaldo C.; Tam, Elizabeth K.; Rose, Keith; Sadikot, Sean; Siegel, David S.; Gutierrez, Martin; Feldman, Tatyana; Goy, André; Pecora, Andrew L.; Biran, Noa; Leslie, Lori A.; Gillio, Alfred P.; Timmapuri, Sarah; Boonstra, Michele; Singer, S. J.; Kaur, Sumeet; Richards, Ernest; Perlin, David S.

doi:10.1172/jci.insight.143196

Cited by 30 publications

(30 citation statements)

References 27 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These observations extend the beneficial effect of CP to intubated patients. Our findings are in accordance with other studies showing shorter duration in the ICU [29,39], reduction of the recovery time and duration of the infection for patients in the ICU [32] and reduction of mortality for intubated patients [38,44]; in contrast other trials, did not reveal a beneficial effect of CP for intubated patients [40,41,47].…”

Section: Discussionsupporting

confidence: 93%

“…Importantly, multivariate analysis confirmed that CP infusion was associated with a significantly reduced risk of death. The beneficial effect of CP infusion on survival demonstrated in our study is in accordance with other studies of similar design showing a survival advantage in CP recipients compared to a control group [37,40,41,44]. Some other studies using comparison to a control group have also shown beneficial results in favor of CP for specific subpopulations, including a survival advantage for non-intubated patients [30], a reduction of disease severity for patients with ARDS [39], and a reduction of mortality for elderly-particularly female-patients admitted to ICU and with comorbidities [38].…”

Section: Discussionsupporting

confidence: 92%

“…In our study, we examined the beneficial effect of CP in patients with severe COVID-19 using a matched propensity score analysis. This strategy has already been used in other trials, resulting in contradictory results [21,23,30,[37][38][39][40][41][44][45][46][47]56]. In our study, the univariate analysis comparing the CP to the control group showed a significantly reduced risk of death.…”

Section: Discussionmentioning

confidence: 51%

“…Most importantly, Joyner et al demonstrated that the 7-and the 30-day mortality rates were significantly increased in patients receiving CP > 4 days from symptom onset [27]. Generally, the time of CP infusion differs significantly in the design of different trials, from 10-22 days [25,33,34,40,[44][45][46]. In the study by Altuntas et al, a higher rate of mechanical ventilation support was observed in patients receiving CP 20 days after diagnosis compared to three interval groups (< 5, 6-10, and 11-15 days, p = 0.001) [23].…”

Section: Discussionmentioning

confidence: 99%

“…The data regarding the efficacy of CP in COVID-19 are gradually increasing, including small case series [25,34,36], observational studies [27,32,33,42,55], matched controlled studies [21,23,30,[37][38][39][40][41][44][45][46][47]56] and a few randomized controlled trials [22,24,26,28,29,35,43], with no definite conclusions. In the observational study by Salazar et al of 25 patients with severe and life threatening disease, the infusion of CP resulted in the improvement of disease severity in 76% of patients [33].…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis

et al. 2021

View full text Add to dashboard Cite

COVID-19 is a global pandemic associated with increased morbidity and mortality. Convalescent plasma (CP) infusion is a strategy of potential therapeutic benefit. We conducted a multicenter phase II study to evaluate the efficacy and safety of CP in patients with COVID-19, grade 4 or higher. To evaluate the efficacy of CP, a matched propensity score analysis was used comparing the intervention (n = 59) to a control group (n = 59). Sixty patients received CP within a median time of 7 days from symptom onset. During a median follow-up of 28.5 days, 56/60 patients fully recovered and 1 patient remained in the ICU. The death rate in the CP group was 3.4% vs. 13.6% in the control group. By multivariate analysis, CP recipients demonstrated a significantly reduced risk of death [HR: 0.04 (95% CI: 0.004–0.36), p: 0.005], significantly better overall survival by Kaplan–Meir analysis (p < 0.001), and increased probability of extubation [OR: 30.3 (95% CI: 2.64–348.9), p: 0.006]. Higher levels of antibodies in the CP were independently associated with significantly reduced risk of death. CP infusion was safe with only one grade 3 adverse event (AE), which easily resolved. CP used early may be a safe and effective treatment for patients with severe COVID-19 (trial number NCT04408209).

show abstract